ImmuPharma plc (IMM.L)
GBp 3.44
(-1.85%)
GBp 3.44
(-1.85%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.02 Million GBP | -4.95% |
| 2022 | -2.91 Million GBP | 42.85% |
| 2021 | -8.7 Million GBP | 6.19% |
| 2020 | -6.84 Million GBP | 12.27% |
| 2019 | -6.65 Million GBP | 21.59% |
| 2018 | -7.81 Million GBP | -14.03% |
| 2017 | -6.85 Million GBP | -11.11% |
| 2016 | -6.19 Million GBP | -39.42% |
| 2015 | -4.42 Million GBP | -37.15% |
| 2014 | -3.22 Million GBP | 21.52% |
| 2013 | -4.29 Million GBP | -1.86% |
| 2012 | -4.11 Million GBP | -13.23% |
| 2011 | -3.56 Million GBP | -46.71% |
| 2010 | -2.42 Million GBP | -123.36% |
| 2009 | 10.4 Million GBP | 110.85% |
| 2008 | 4.91 Million GBP | 250.12% |
| 2007 | -3.28 Million GBP | 0.0% |
| 2005 | -1.49 Million GBP | -8864.71% |
| 2004 | 17 Thousand GBP | 750.0% |
| 2003 | 2000.00 GBP | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -372.69 Thousand GBP | 0.0% |
| 2024 Q1 | -372.69 Thousand GBP | 57.3% |
| 2023 Q3 | -866.23 Thousand GBP | 30.12% |
| 2023 Q1 | -619.81 Thousand GBP | 51.54% |
| 2023 FY | - GBP | -9.1% |
| 2023 Q4 | -872.89 Thousand GBP | -0.77% |
| 2023 Q2 | -1.23 Million GBP | -100.0% |
| 2022 Q1 | -791.43 Thousand GBP | 64.16% |
| 2022 FY | - GBP | 42.85% |
| 2022 Q2 | -1.63 Million GBP | -106.25% |
| 2022 Q3 | -664.25 Thousand GBP | 59.31% |
| 2022 Q4 | -1.27 Million GBP | -92.56% |
| 2021 Q1 | -1.07 Million GBP | 58.79% |
| 2021 Q2 | -2.99 Million GBP | -178.88% |
| 2021 Q3 | -1.44 Million GBP | 51.59% |
| 2021 Q4 | -2.2 Million GBP | -52.36% |
| 2021 FY | - GBP | 6.19% |
| 2020 Q3 | -1.3 Million GBP | 53.71% |
| 2020 Q2 | -2.81 Million GBP | -100.0% |
| 2020 FY | - GBP | 12.27% |
| 2020 Q1 | -1.4 Million GBP | 54.27% |
| 2020 Q4 | -2.6 Million GBP | -100.0% |
| 2019 Q1 | -1.61 Million GBP | 16.55% |
| 2019 FY | - GBP | 21.59% |
| 2019 Q3 | -1.47 Million GBP | 54.33% |
| 2019 Q2 | -3.23 Million GBP | -100.0% |
| 2019 Q4 | -3.07 Million GBP | -108.11% |
| 2018 Q2 | -2.03 Million GBP | 0.0% |
| 2018 Q4 | -1.93 Million GBP | 0.0% |
| 2018 Q3 | -1.93 Million GBP | 4.64% |
| 2018 Q1 | -2.03 Million GBP | -2.44% |
| 2018 FY | - GBP | -14.03% |
| 2017 FY | - GBP | -11.11% |
| 2017 Q4 | -1.98 Million GBP | 0.0% |
| 2017 Q3 | -1.98 Million GBP | -27.07% |
| 2017 Q2 | -1.56 Million GBP | 0.0% |
| 2017 Q1 | -1.56 Million GBP | 4.94% |
| 2016 Q3 | -1.64 Million GBP | -3.36% |
| 2016 FY | - GBP | -39.42% |
| 2016 Q2 | -1.59 Million GBP | 0.0% |
| 2016 Q1 | -1.59 Million GBP | -7.21% |
| 2016 Q4 | -1.64 Million GBP | 0.0% |
| 2015 FY | - GBP | -37.15% |
| 2015 Q2 | -737.37 Thousand GBP | -0.0% |
| 2015 Q3 | -1.48 Million GBP | -101.16% |
| 2015 Q4 | -1.48 Million GBP | 0.0% |
| 2015 Q1 | -737.37 Thousand GBP | 5.11% |
| 2014 Q4 | -777.09 Thousand GBP | 0.0% |
| 2014 Q2 | -885.77 Thousand GBP | 0.0% |
| 2014 Q1 | -885.77 Thousand GBP | 28.12% |
| 2014 FY | - GBP | 21.52% |
| 2014 Q3 | -777.09 Thousand GBP | 12.27% |
| 2013 Q1 | -912.8 Thousand GBP | 16.36% |
| 2013 Q3 | -1.23 Million GBP | -35.0% |
| 2013 Q4 | -1.23 Million GBP | 0.0% |
| 2013 FY | - GBP | -1.86% |
| 2013 Q2 | -912.8 Thousand GBP | 0.0% |
| 2012 FY | - GBP | -13.23% |
| 2012 Q4 | -1.09 Million GBP | 0.0% |
| 2012 Q3 | -1.09 Million GBP | 0.0% |
| 2011 FY | - GBP | -46.71% |
| 2010 FY | - GBP | -123.36% |
| 2009 FY | - GBP | 110.85% |
| 2008 FY | - GBP | 250.12% |
| 2007 FY | - GBP | 0.0% |
| 2006 Q2 | - GBP | 0.0% |
| 2005 FY | - GBP | -8864.71% |
| 2004 FY | - GBP | 750.0% |
| 2003 FY | - GBP | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|